Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
25 Cards in this Set
- Front
- Back
- 3rd side (hint)
|
Tricyclic Antidepressants (TCA's)
100-350 mg/day |
Tricyclic Antidepressants (TCA's)
desipramine/Norpramin, Pertofrane |
Tricyclic Antidepressants (TCA's)
Relief of Symptoms: 2-4 wk Side Efffects: Dry mouth, tremors, blurred vision, bloating and weight gain, urinary retention. Sedation Level/Half-Life: Less sedating than other TCAs. |
|
|
Tricyclic Antidepressants (TCA's)
100-150 mg/day PO in divided doses; gradually increase to 200 mg/day; if no response after 2 wk, may be increased to 250-300 mg/day. |
Tricyclic Antidepressants (TCA's)
imipramin/Tofranil |
Tricyclic Antidepressants (TCA's)
Relief of Symptoms: Decreased anxiety immediately evident; antidepressant response may require 2-3 wk. Side Effects: Sedation, anticholinergic effects, confusion, disturbed concentration, dry mouth, constipation, orthostatic hypotension. Sedation Level/Half-Life: May abe sedating, at least initially; half-life is 8-16 hr. |
|
|
Tricyclic Antidepressants (TCA's)
25 mg TID-QID PO; doses>150 mg/day not recommended |
Tricyclic Antidepressants (TCA's)
nortriptyline/Pamelor |
Tricyclic Antidepressants (TCA's)
Relief of Symptoms: Gradual; 2-4 wk. Side Effects: Sedation and anticholinergic effects, confusion (especially in elderly), disturbed concentration; seizures, orthostatic hypotension, dry mouth, constipation, nausea; avoid abrupt withdrawal of medication. Sedation Level/Half-Life: Sedating; half-life is 18-28 hr. |
|
|
Tricyclic Antidepressants (TCA's)
25mg PO TID for mild to moderate anxiety and depression; 50 mg PO TID (up to 300 mg/day) for more sever anxiety and depression. |
Tricyclic Antidepressants (TCA's)
doxepin/Sinequan |
Tricyclic Antidepressants (TCA's)
Relief of Symptoms: 2-4 wk Side Effects: Sedation, anticholinergic effects, confusion, disturbed concentration, dry mouth, constipation, orthostatic hypotension. Sedation Level/Half-Life: May be sedating; half-life is 8-25 hr. |
|
|
Tricyclic Antidepressants (TCA's)
Initially, 75-100 mg/day PO in divided doses; gradually increase to 200-300 mg/day PO. |
Tricyclic Antidepressants (TCA's)
amitriptyline/Elavil |
Tricyclic Antidepressants (TCA's)
Relief of Symptoms: Beginning relief of symptoms may take 2-4 wk. Side Effects: Sedation, anticholinergic effects, confusion, disturbed concentration, dry mouth, constipation, orthostatic hypotension. Sedation Level/Half-Life: May be sedating; half-life is 10-50 hr. |
|
|
Tricyclic Antidepressants (TCA's)
5-40 mg/day PO in three to four divided doses with gradual increase to 60 mg/day; make increases in AM dose. |
Tricyclic Antidepressants (TCA's)
protriptyline/Vivactil |
Tricyclic Antidepressants (TCA's)
Relief of Symptoms: 24-30 hr. Side Effects: Sedation and anticholinergic effects, confusion (especially in elderly), disturbed concentration, seizures, orthostatic hypotension, myocardial infarction, stroke dry mouth, constipation. Sedation Level/Half-Life: Activating; half-life is 67-89 hr. |
|
|
Tricyclic Antidepressants (TCA's)
50 mg PO BID-TID with dradual increase to 100 mg BID-TID by end of first week; increase above 300 mg/day only if this dosage ineffective for at least 2 wk. |
Tricyclic Antidepressants (TCA's)
amoxapine/Asendin |
Tricyclic Antidepressants (TCA's)
Relief of Symptoms: Gradual; 2-4 wk Side Effects: Disturbed concentration, sedation and anticholinergic effects, confusion, orthostatic hypotension, dry mouth, constipation; avoid abrupt withdrawal of medication. Sedation Level/Half-Life: Sedating; half-life is 8-30 hr. |
|
|
Tricyclic Antidepressants (TCA's)
Inpatient: 100 mg/day PO in divided doses with gradual increase to 200 mg/day; outpatients; initially 75 mg/day PO in divided doses with increase to 150 mg/day; maintenance dose is 50-150 mg/day given as single HS dose. |
Tricyclic Antidepressants (TCA's)
trimipramine/Surmontil |
Tricyclic Antidepressants (TCA's)
Relief of Symptoms: 2 hr. Side Effects: Sedation and anticholinergic effects, confusion (especially in elderly), disturbed concentration, orthostatic hypotension, mycardial infarction, precipitation of congestive heart failure, stroke, dry mouth, constipation; avoid abrupt withdrawal of medication. Sedation Level/Half-Life: Sedating; half-life is 7-30 hr. |
|
|
Tricyclic Antidepressants (TCA's)
75-250 mg/day |
Tricyclic Antidepressants (TCA's)
clomipramine/Anafranil |
Tricyclic Antidepressants (TCA's)
Relief of Symptoms: Can be lethal in a suicide attempt; 2-4 wk; side effects may be discouraging. Side Effects: Cognitive impairment, memory loss, confusion, dry mouth, tremors, blurred vision, bloating and weight gain, urinary retention. Sedation Level/Half-Life: Sedating |
|
|
Tetracyclic Antidepressant
Initially 75 mg/day PO with gradual increases in 25 mg increments; most patients respond to 150 mg/day, but some may require 225 mg/day; severe depression may require 100-150 mg/day PO with gradual increase to 300 mg/day; usual maintenance dose is 75-150 mg/day PO. |
Tricyclic Antidepressants (TCA's)
maprotiline/Ludiomil |
Tricyclic Antidepressants (TCA's)
Relief of Symptoms: Gradual; 2-4 wk. Side Effects: Sedation and anticholinergic effects, confusion (especially in elderly), disturbed concentration, seizures, orthostatic hypotension, dry mouth, constipation, nausea; avoid abrupt withdrawal of medication. Sedation Level/Half Life: Sedating; half-life is 27-58 hr. |
|
|
Monoamine Oxidase Inhibitors-A
Initially, 15 mg PO TID; increase dose to at least 60 mg/day at rapid pace according to client tolerance; some may require 90 mg/day. |
Monoamine Oxidase Inhibitors-A
phenelzine sulfate/Nardil |
Monoamine Oxidase Inhibitors-A
Relief of Symptoms: Up to 4 wk for maximum response. Side Effects: Dizziness, vertigo, headache, overactivity, hyperreflexia, tremors, muscle twitching, mania, hypomania, jitteriness, confusion, memory impairment, insomnia, weakness, fatigue, drowsiness, restlessness, overstimulation, increased anxiety, agitation, blurred vision, sweating, constipation, diarrhea, nausea, abdominal pain, edema, dry mouth, anorexia, weight changes, hypertensive crisis, orthostatic hypotension, disturbed cardiac rate and rhythm. Sedation Level/Half-Life: Likely to energize; half-life is unknown. |
|
|
Monoamine Oxidase Inhibitors-A
Most effective dose usually is 30 mg/day PO in divided doses; in no improvement with 2 wk, increase dosage in 10 mg/day increments to a maximum of 60 mg/day. |
Monoamine Oxidase Inhibitors-A
tranylcypromine/Parnate |
Monoamine Oxidase Inhibitors-A
Relief of Symptoms: Improvement within 48 hr to 3 wk. Side Effects: Dizziness, vertigo, headache, overactivity, hyperreflexia, tremors, muscle twitching, mania, hypomania, jitteriness, confusion, memory impairment, insomnia, weakness, fatigue, drowsiness, restlessness, overstimulation, increased anxiety, agitaion, blurred vision, sweating, constipation, diarrhea, nausea, abdominal pain, edema, dry mouth, anorexia, weight changes, hypertensive crises, orthostatic hypotencsion, disturbed cardiac rate and rhythm. Sedation Level/Half-Life: May be stimulating, especially to clients with agitation or schizophrenia; half-life is unknown. |
|
|
Monoamine Oxidase Inhibitors-A
30-60 mg/day |
Monoamine Oxidase Inhibitors-A
isocarboxazid/Marplan |
Monoamine Oxidase Inhibitors-A
Rlief of Symptoms: Improvement seen within 3-6 wks. Side Effects: Similar to Parnate and Nardil. Sedation Level/Half-Life: Half-life is unknown; energizing. |
|
|
Monoamine Oxidase Inhibitors-B
Transdermal patch; initially apply a 6 mg patch that must be changed every 24 hours. The dose can be increased every 2 wk to a mzximum of 9 mg. |
Monoamine Oxidase Inhibitors-B
selegiline transdermal/EmSam |
Monoamine Oxidase Inhibitors-B
Relief of Symptoms: Up to 7 days. Side Effects: Headache, increased blood pressure. Same dietary and OTC precautions as for MAOI-A. Sedation Level/Half-Life: Activating; half-life is 10 hours. |
|
|
Selective Reuptake Inhibitors (SARIs) (Seratonin-2 Antagonist/Reuptake Inhibitor)
200 mg/day PO in two divided doses; increase at 1 wk intervals to 100-200 mg/day; usual range is 300-600 mg/day. |
Selective Reuptake Inhibitors (SARIs) (Seratonin-2 Antagonist/Reuptake Inhibitor)
nefazodone/Serzone |
Selective Reuptake Inhibitors (SARIs) (Seratonin-2 Antagonist/Reuptake Inhibitor)
Relief of Symptoms: Beginning relief of symptoms may take 2-4 wk. Side Effects: Headache, nervousness, insomnia, drowsiness, light-headedness, nausea, vomiting, diarrhea, dry mouth, anorexia, dyspepsia, constipation, taste changes, sweating, rash, pruritus. Sedation Level/Half-Life: May cause nervousness or insomnia or be slightly sedating; half-life is 2-3 days. |
|
|
Selective Reuptake Inhibitors (SARIs) (Seratonin-2 Antagonist/Reuptake Inhibitor)
Initially, 150 mg/day PO with increase of 50 mg/day every 3-4 days; maximum dose should not exceed 600 mg/day in divided doses for severely depressed clients. |
Selective Reuptake Inhibitors (SARIs) (Seratonin-2 Antagonist/Reuptake Inhibitor)
trazodone/Desyrel |
Selective Reuptake Inhibitors (SARIs) (Seratonin-2 Antagonist/Reuptake Inhibitor)
Relief of Symptoms: 10-14 days and up to 2-4 wk. Side Effects: Anger, hostility, agitation, nightmares/vivid dreams, hallucinations, delusions, hypomania, confusion, disorientation, decreased concentration, impaired memory, impaired speech, dizziness, lack of coordination, drowsiness, fatigue, gastric disorder, decreased/increased appetite, dry mouth, bad taste in mouth, nausea, vomiting, diarrhea, flatulence, constipation, hypertension, hypotension, shortness of breath, syncope, tachycardia, palpitations, decreased libido, allergic skin conditions, edema. Sedation Level/Half-Life: May cause drowsiness or agitation; half-life is 3-6 hr and then 5-9 hr. |
|
|
Selective NE/DA Reuptake Inhibitors
300-400 mg |
Selective NE/DA Reuptake Inhibitors
bupropion/Wellbutrin |
Selective NE/DA Reuptake Inhibitors
Relief of Symptoms: 10-14 days. Side Effects: Weight loss, agitation, risk of seizures, relative absence of sexual dysfunction. Sedation Level/Half-Life: Low; if anything, energizing; half-life is 8-24 hr. |
|
|
Selective NE/DA Reuptake Inhibitors
Initial dose of 15 mg/d PO as a single evening dose; may be increased up to 45 mg/day PO as needed. |
Selective NE/DA Reuptake Inhibitors
mirtazapine/Remeron |
Selective NE/DA Reuptake Inhibitors
Relief of Symptoms: Clinical response in 3-7 days or up to 2-3 wk. Side Effects: Sedation and anticholinergic effects, confusion, disturbed concentration, dry mouth, constipation, nausea, agranulocytosis, neutropenia. Sedation Level/Half-Life: May be sedating; half-life is 20-40 hr. |
|
|
Selective Serotonin Reuptake Inhibitors (SSRIs)
Initial dose of 20 mg/day PO in AM; if no improvement after several weeks, increase dose on a BID schedule up to 80 mg/day PO. |
Selective Serotonin Reuptake Inhibitors (SSRIs)
fluoxetine/Prozac |
Selective Serotonin Reuptake Inhibitors (SSRIs)
Relief of Symptoms: Up to 4 wk. Side Effects: Headache, nervousness, insomnia, drowsiness, anxiety, tremor, dizziness, light-headedness, nausea, vomiting, diarrhea, dry mouth, anorexia, dyspepsia, constipation, taste changes, upper respiratory infections, pharyngitis, painful menstruation, sexual dysfunction, frequency, sweating, rash pruritus, weight loss, asthenia, fever. Sedation Level/Half-Life: May be energizing; half-life is 2-9 days. |
|
|
Selective Serotonin Reuptake Inhibitors (SSRIs)
20 mg/day PO as a single dose; may be increased up to 50 mg/day |
Selective Serotonin Reuptake Inhibitors (SSRIs)
paroxetine/Paxil |
Selective Serotonin Reuptake Inhibitors (SSRIs)
Relief of Symptoms: 1-4 wk Side Effects: Somnolence, dizziness, insomnia, tremor, nervousness, headache, nausea, dry mouth, constipation, diarrhea, ejaculatory disorders, male genital disorders, sweating, headache, asthenia. Sedation Level/Half-Life: May be energizing; half-life is 1 hr. |
|
|
Selective Serotonin Reuptake Inhibitors (SSRIs)
Administer daily, AM or PM, 50 mg/day PO; may be increased up to 200 mg/day; increases occur at 1 wk intervals. |
Selective Serotonin Reuptake Inhibitors (SSRIs)
sertraline/Zoloft |
Selective Serotonin Reuptake Inhibitors (SSRIs)
Relief of Symptoms: Beginning relief of symptoms may take 2-4 wk. Side Effects: Headache, nervousness, drowsiness, anxiety, tremor, dizziness, insomnia, nausea, diarrhea, dry mouth, rhinitis, painful menstruation, sweating. Sedation Level/Half-Life: May be energizing; half-life is 26 hr. |
|
|
Selective Serotonin Reuptake Inhibitors (SSRIs)
Initially 50 mg PO HS with increase in 50 mg increments at 4 to 7 day intervals; usual range is 100-300 mg/day with divided doses and larger dose at HS. |
Selective Serotonin Reuptake Inhibitors (SSRIs)
fluvoxamine maleate/Luvox |
Selective Serotonin Reuptake Inhibitors (SSRIs)
Relief of Symptoms: 2-4 wks. Side Effects: Headache, nervousness, insomnia, drowsiness, anxiety, tremor, dizziness, light-headedness, sweating, rash, pruritus, nausea, vomiting, diarrhea, dry mouth, anorexia, dyspepsia, constipation, taste changes, sexual dysfunction, frequency, upper respiratory infection, pharyngitis; avoid abrupt withdrawal of medication. Sedation Level/Half-Life: May be activating; half-life is 15 hr. |
|
|
Selective Serotonin Reuptake Inhibitors (SSRIs)
Initially 20 mg PO/day as a single dose; may be increased to 40 mg/day if needed. |
Selective Serotonin Reuptake Inhibitors (SSRIs)
citalopram/Celexa |
Selective Serotonin Reuptake Inhibitors (SSRIs)
Relief of Symptoms: 4-6 wk Side Effects: Nausea, dry mouth, sweating, somnolence, dizziness, insomnia, ejaculatory disorders. Sedation Level/Half-Life: May be energizing; half-life is 35 hr. |
|
|
Selective Serotonin Reuptake Inhibitors (SSRIs)
Initially 5 my PO/day as a single dose; may be increased to 10mg/day if needed. |
Selective Serotonin Reuptake Inhibitors (SSRIs)
e-citalopram/Lexapro |
Selective Serotonin Reuptake Inhibitors (SSRIs)
Relief of Symptoms: 4-6 wk. Side Effects: Nausea, dry mouth, sweating, somnolence, dizziness, insomnia, ejaculatory disorders. Sedation Level/Half-Life: May be energizing; half-life is 35 hr. |
|
|
Dopamine Agonist
Oral doses Week 1: 0.125 mg TID Week 2: 0.25 mg TID Week 3: 0.5 mg TID Week 4: 0.75 mg TID Week 5: 1 mg TID Week 6: 1.25 mg TID Week 7: 1.5 mg TID |
Dopamine Agonist
pramipexole/Mirapex |
Dopamine Agonist
Relief of symptoms at therapeutic dose. Side Effects: Headache, dizziness, insomnia, somnolence, nausea, constipation, asthenia. Sedation Level/Half-Life: May cause sleepiness; half-life is 8 hr. |
